B · Normal
[FDA warns that GLP-1 antidiabetic drugs may increase the risk of eye disease] On November 11, the U.S. Food and Drug Administration issued a notice on November 9 that the use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs may increase the risk of a rare eye disease that may lead to permanent vision loss, and required all marketing application holders of related drugs to add risk warning information to the drug inserts. The drugs involved include semaglutide, liraglutide, and tilpotide.
Comments